Expasy logo

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot Q9NP85: Variant p.Arg3Gly

Podocin
Gene: NPHS2
Feedback?
Variant information Variant position: help 3 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help LP/P [Disclaimer] The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance
Residue change: help From Arginine (R) to Glycine (G) at position 3 (R3G, p.Arg3Gly). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Change from large size and basic (R) to glycine (G) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help -2 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page
Variant description: help In NPHS2. Any additional useful information about the variant.


Sequence information Variant position: help 3 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 383 The length of the canonical sequence.
Location on the sequence: help ME R RARSSSRESRGRGGRTPHKE The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: help The multiple alignment of the region surrounding the variant against various orthologous sequences. 
Human                         MERRARSSSRESRGRGGRTPHKE

Mouse                         MDSRARSSSREAHGRSSRSSSRD

Rat                           MDSRARSSSRKTHGRGSRSSSRD
Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
TypePositionsDescription
Chain 1 – 383 Podocin
Topological domain 1 – 102 Cytoplasmic
Region 1 – 76 Disordered
Compositional bias 1 – 37 Basic and acidic residues



Literature citations
NPHS2 (podicin) mutations in Turkish children with idiopathic nephrotic syndrome.
Berdeli A.; Mir S.; Yavascan O.; Serdaroglu E.; Bak M.; Aksu N.; Oner A.; Anarat A.; Donmez O.; Yildiz N.; Sever L.; Tabel Y.; Dusunsel R.; Sonmez F.; Cakar N.;
Pediatr. Nephrol. 22:2031-2040(2007)
Cited for: VARIANTS NPHS2 GLY-3; THR-18; MET-26; MET-28; GLN-30; LYS-30; LEU-39; THR-89; THR-115; LEU-122; TRP-124; VAL-192; ALA-211; THR-213; GLY-218; ASP-228; LEU-229; ASN-267; LEU-268; LEU-276; ALA-301 DEL; GLN-322 AND GLY-370; NPHS2 mutations in steroid-resistant nephrotic syndrome: a mutation update and the associated phenotypic spectrum.
Bouchireb K.; Boyer O.; Gribouval O.; Nevo F.; Huynh-Cong E.; Moriniere V.; Campait R.; Ars E.; Brackman D.; Dantal J.; Eckart P.; Gigante M.; Lipska B.S.; Liutkus A.; Megarbane A.; Mohsin N.; Ozaltin F.; Saleem M.A.; Schaefer F.; Soulami K.; Torra R.; Garcelon N.; Mollet G.; Dahan K.; Antignac C.;
Hum. Mutat. 35:178-186(2014)
Cited for: VARIANTS NPHS2 SER-97; PRO-107; SER-122; VAL-175; TYR-183; LYS-281; LYS-296; VAL-309; ILE-315 AND GLY-333; VARIANTS LEU-20; GLN-237 AND GLN-264;
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.